In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 639 ( 2022-04-06)
Abstract:
Vaccines that elicit broadly neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will be essential for curbing the ongoing coronavirus disease 2019 (COVID-19) pandemic. Here, Huang et al . evaluated the immunological impact of enzymatically removing glycan shields from the SARS-CoV-2 spike (S) protein. The authors found that immunizing hamsters or mice with S protein lacking glycan shields, termed S MG , elicited robust and broadly reactive immune responses. Vaccinated mice were protected from challenge with the alpha, gamma, and delta variants of concern. Antibodies isolated from vaccinated animals could also neutralize the omicron variant. Together, these data support further investigation into S MG as a candidate SARS-CoV-2 vaccine.
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abm0899
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022